Zanamivir

Drug Profile

Zanamivir

Alternative Names: 4-guanidino Neu5Ac2en; GG 167; GR 121167; GR 121167X; Relenza

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biota Holdings; Monash University
  • Developer GlaxoSmithKline
  • Class Antivirals; Guanidines; Pyrans; Sialic acids
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
  • 01 Jun 2015 GlaxoSmithKline completes a phase I trial in Healthy volunteers in China (NCT02377401)
  • 20 Apr 2015 Zanamivir is in phase-II/III development for Influenza virus infections in World (IV, infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top